Compile Data Set for Download or QSAR
Report error Found 58 Enz. Inhib. hit(s) with all data for entry = 10573
TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422811(US10508107, Example 17 | US11312711, Example 17)
Affinity DataEC50:  673nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250376(US9452980, 286 | US10501411, Example 286 | US11312...)
Affinity DataEC50:  447nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422807(US10508107, Example 13 | US11312711, Example 13)
Affinity DataEC50:  404nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250298(US9452980, 208 | US10501411, Example 208 | US11312...)
Affinity DataEC50:  212nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422809(US10508107, Example 15 | US11312711, Example 15)
Affinity DataEC50:  663nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250374(US9452980, 284 | US10501411, Example 284 | US11312...)
Affinity DataEC50:  203nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422804(US10508107, Example 10 | US11312711, Example 10)
Affinity DataEC50:  184nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422810(US10508107, Example 16 | US11312711, Example 16)
Affinity DataEC50:  666nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422803(US10508107, Example 9 | US11312711, Example 9)
Affinity DataEC50:  144nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422802(US10508107, Example 8 | US11312711, Example 8)
Affinity DataEC50:  109nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250361(US9452980, 271 | US10501411, Example 271 | US11312...)
Affinity DataEC50:  84.9nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422812(US10508107, Example 18 | US11312711, Example 18)
Affinity DataEC50:  827nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422800(US10508107, Example 6 | US11312711, Example 6)
Affinity DataEC50:  80nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422814(US10508107, Example 20 | US11312711, Example 20)
Affinity DataEC50:  2.48E+3nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422652(US10508107, Example 1 | 5-Ethyl-4-methyl-N-[4-[(2S...)
Affinity DataEC50:  58.5nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422653(US10508107, Example 2 | US11312711, Example 2)
Affinity DataEC50:  263nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250359(US9452980, 269 | US10501411, Example 269 | US11312...)
Affinity DataEC50:  37.7nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422813(US10508107, Example 19 | US11312711, Example 19)
Affinity DataEC50:  1.03E+3nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250298(US9452980, 208 | US10501411, Example 208 | US11312...)
Affinity DataEC50:  61.9nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetTrace amine-associated receptor 1(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422671(US10508107, Example 5 | US11312711, Example 5)
Affinity DataEC50:  65.6nMAssay Description:For the construction of expression plasmids the coding sequences of human TAAR1 were amplified from genomic DNA essentially as described by Lindemann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422800(US10508107, Example 6 | US11312711, Example 6)
Affinity DataIC50: 1.31E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422803(US10508107, Example 9 | US11312711, Example 9)
Affinity DataIC50: 4.46E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422810(US10508107, Example 16 | US11312711, Example 16)
Affinity DataIC50: 8.98E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422809(US10508107, Example 15 | US11312711, Example 15)
Affinity DataIC50: 9.65E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250359(US9452980, 269 | US10501411, Example 269 | US11312...)
Affinity DataIC50: 9.84E+3nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422814(US10508107, Example 20 | US11312711, Example 20)
Affinity DataIC50: 1.08E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422802(US10508107, Example 8 | US11312711, Example 8)
Affinity DataIC50: 1.08E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250361(US9452980, 271 | US10501411, Example 271 | US11312...)
Affinity DataIC50: 1.14E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250298(US9452980, 208 | US10501411, Example 208 | US11312...)
Affinity DataIC50: 1.43E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250374(US9452980, 284 | US10501411, Example 284 | US11312...)
Affinity DataIC50: 1.74E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422804(US10508107, Example 10 | US11312711, Example 10)
Affinity DataIC50: 3.17E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250298(US9452980, 208 | US10501411, Example 208 | US11312...)
Affinity DataIC50: 4.97E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422813(US10508107, Example 19 | US11312711, Example 19)
Affinity DataIC50: 6.05E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422807(US10508107, Example 13 | US11312711, Example 13)
Affinity DataIC50: 6.60E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250376(US9452980, 286 | US10501411, Example 286 | US11312...)
Affinity DataIC50: 7.32E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422671(US10508107, Example 5 | US11312711, Example 5)
Affinity DataIC50: 8.17E+4nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422652(US10508107, Example 1 | 5-Ethyl-4-methyl-N-[4-[(2S...)
Affinity DataIC50: 2.17E+5nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422811(US10508107, Example 17 | US11312711, Example 17)
Affinity DataIC50: 5.18E+5nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422812(US10508107, Example 18 | US11312711, Example 18)
Affinity DataIC50: 7.12E+5nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of the test items on hERG (human-ether-a-go-go related gene) potassium chann...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422803(US10508107, Example 9 | US11312711, Example 9)
Affinity DataKi:  480nMAssay Description:Binding to dopamine transporter (DAT) in vitro. Human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with human D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250361(US9452980, 271 | US10501411, Example 271 | US11312...)
Affinity DataKi:  790nMAssay Description:Binding to dopamine transporter (DAT) in vitro. Human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with human D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422807(US10508107, Example 13 | US11312711, Example 13)
Affinity DataKi:  1.31E+3nMAssay Description:Binding to dopamine transporter (DAT) in vitro. Human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with human D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422671(US10508107, Example 5 | US11312711, Example 5)
Affinity DataKi:  1.52E+3nMAssay Description:Binding to dopamine transporter (DAT) in vitro. Human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with human D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250298(US9452980, 208 | US10501411, Example 208 | US11312...)
Affinity DataKi:  1.78E+3nMAssay Description:Binding to dopamine transporter (DAT) in vitro. Human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with human D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250374(US9452980, 284 | US10501411, Example 284 | US11312...)
Affinity DataKi:  2.33E+3nMAssay Description:Binding to dopamine transporter (DAT) in vitro. Human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with human D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250298(US9452980, 208 | US10501411, Example 208 | US11312...)
Affinity DataKi:  2.50E+3nMAssay Description:Binding to dopamine transporter (DAT) in vitro. Human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with human D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422800(US10508107, Example 6 | US11312711, Example 6)
Affinity DataKi:  5.93E+3nMAssay Description:Binding to dopamine transporter (DAT) in vitro. Human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with human D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM250376(US9452980, 286 | US10501411, Example 286 | US11312...)
Affinity DataKi:  7.32E+3nMAssay Description:Binding to dopamine transporter (DAT) in vitro. Human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with human D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422802(US10508107, Example 8 | US11312711, Example 8)
Affinity DataKi:  9.77E+3nMAssay Description:Binding to dopamine transporter (DAT) in vitro. Human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with human D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM422811(US10508107, Example 17 | US11312711, Example 17)
Affinity DataKi:  1.03E+4nMAssay Description:Binding to dopamine transporter (DAT) in vitro. Human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with human D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 58 total ) | Next | Last >>
Jump to: